Thanks for the opportunity. So , my first question is on the insulin opportunities. For the RHI cartridge market, what is the market share that we are targeting once the innovator is out?
Got it. Okay. And the second question is, you all have mentioned that the lower OCF to EBITDA ratio on account of an increase in GST receivables and statutory liabilities. So, could you please provide some more clarity on this?